Thomas Hengelage

463 total citations
14 papers, 385 citations indexed

About

Thomas Hengelage is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Thomas Hengelage has authored 14 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Thomas Hengelage's work include Histone Deacetylase Inhibitors Research (4 papers), Bacterial Genetics and Biotechnology (3 papers) and RNA and protein synthesis mechanisms (3 papers). Thomas Hengelage is often cited by papers focused on Histone Deacetylase Inhibitors Research (4 papers), Bacterial Genetics and Biotechnology (3 papers) and RNA and protein synthesis mechanisms (3 papers). Thomas Hengelage collaborates with scholars based in Switzerland, United States and Germany. Thomas Hengelage's co-authors include Hedda K. Hoffschulte, Hans‐Georg Koch, Karl-Ludwig Schimz, Bernd Mechler, Matthias Müller, Juan MacFarlane, Christoph Neumann‐Haefelin, Margaret M. Woo, Matthias Müller and Beate Wieseler and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of Bacteriology.

In The Last Decade

Thomas Hengelage

14 papers receiving 377 citations

Peers

Thomas Hengelage

GENET

ECOLO

ONCOL

IMMUN

Hongjin Huang China

Adrian E. Rice United States

Armando C. Rodriguez United States

Leena Harju Finland

Shizue Katoh Japan

Mary Purucker United States

Jun Ohkawa Japan

Hetty A.A.M. van Teeffelen Netherlands

C. Hu United States

Szymon K. Filip Greece

Hongjin Huang China

Thomas Hengelage

245 ×0.9

114 ×0.8

GENET

52 ×0.7

ECOLO

24 ×0.4

ONCOL

56 ×1.6

IMMUN

Citations per year, relative to Thomas Hengelage Thomas Hengelage (= 1×) peers Hongjin Huang

Countries citing papers authored by Thomas Hengelage

Since Specialization

Citations

This map shows the geographic impact of Thomas Hengelage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Hengelage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Hengelage more than expected).

Fields of papers citing papers by Thomas Hengelage

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Hengelage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Hengelage. The network helps show where Thomas Hengelage may publish in the future.

Co-authorship network of co-authors of Thomas Hengelage

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Hengelage. A scholar is included among the top collaborators of Thomas Hengelage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Hengelage. Thomas Hengelage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Ji, Yan, Eugene Tan, Thomas Hengelage, Michelle Quinlan, & Bart S. Hendriks. (2023). Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs. Clinical Pharmacology & Therapeutics. 114(2). 288–302. 2 indexed citations

Braña, Irene, Geoffrey I. Shapiro, Melissa L. Johnson, et al.. (2021). Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 3005–3005. 47 indexed citations

Juric, Dejan, Jordi Rodón, Todd M. Bauer, et al.. (2015). 342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors. European Journal of Cancer. 51. S68–S68. 2 indexed citations

Feld, Ronald, Margaret M. Woo, Natasha B. Leighl, et al.. (2013). A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 72(4). 747–755. 13 indexed citations

Hamberg, Paul, Margaret M. Woo, Lin‐Chi Chen, et al.. (2011). Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemotherapy and Pharmacology. 68(3). 805–813. 42 indexed citations

Shapiro, Geoffrey I., Richard C. Frank, Thomas Hengelage, et al.. (2011). The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 69(2). 555–562. 30 indexed citations

Woo, Margaret M., et al.. (2010). A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer.. Journal of Clinical Oncology. 28(15_suppl). e13089–e13089. 2 indexed citations

Vogt, Bruno, et al.. (2009). Dose-Dependent Acute and Sustained Renal Effects of the Endothelin Receptor Antagonist Avosentan in Healthy Subjects. Clinical Pharmacology & Therapeutics. 85(6). 628–634. 30 indexed citations

Dieterle, W. & Thomas Hengelage. (2009). Absolute bioavailability and pharmacokinetics of avosentan in man. International Journal of Clinical Pharmacology and Therapeutics. 47(9). 587–594. 3 indexed citations

10.

Dieterle, W. & Thomas Hengelage. (2008). Influence of food intake on the pharmacokinetics of avosentan in man. International Journal of Clinical Pharmacology and Therapeutics. 46(9). 453–458. 1 indexed citations

11.

Koch, Hans‐Georg, Thomas Hengelage, Christoph Neumann‐Haefelin, et al.. (1999). In Vitro Studies with Purified Components Reveal Signal Recognition Particle (SRP) and SecA/SecB as Constituents of Two Independent Protein-targeting Pathways ofEscherichia coli. Molecular Biology of the Cell. 10(7). 2163–2173. 137 indexed citations

12.

Koch, Hans‐Georg, et al.. (1998). Requirements for the Translocation of Elongation-arrested, Ribosome-associated OmpA across the Plasma Membrane ofEscherichia coli. Journal of Biological Chemistry. 273(22). 13898–13904. 44 indexed citations

13.

Wächter, Elmar, Annette Neubüser, Hedda K. Hoffschulte, et al.. (1997). Comparative characterization of SecA from the alpha-subclass purple bacterium Rhodobacter capsulatus and Escherichia coli reveals differences in membrane and precursor specificity. Journal of Bacteriology. 179(12). 4003–4012. 19 indexed citations

14.

Falkenberg, Frank W., et al.. (1993). A simple and inexpensive high density dialysis tubing cell culture system for the in vitro production of monoclonal antibodies in high concentration. Journal of Immunological Methods. 165(2). 193–206. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact